Second-line chemotherapy in patients with small-cell lung cancer: Phase II trial of ZD0473

被引：0

作者：

Schiller, J ^{[1
]}

Bonomi, G ^{[1
]}

Modiano, M ^{[1
]}

Bonomi, P ^{[1
]}

Cornett, P ^{[1
]}

Kelly, K ^{[1
]}

Koehler, M ^{[1
]}

机构：

[1] Univ Wisconsin, Ctr Comprehens Canc, Madison, WI 53706 USA

来源：

LUNG CANCER: CURRENT TOPICS | 2001年

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

ZD0473 is a new generation platinum drug designed to deliver an extended spectrum of antitumour activity and overcome platinum resistance mechanisms. We present interim results from a Phase II trial of ZD0473 in patients with small-cell lung cancer (SCLC).

引用

页码：335 / 339

页数：5

共 50 条

[21] Phase II trial of ZD0473 in patients with mesothelioma who had relapsed after one prior chemotherapy regimen
Giaccone, G
O'Brien, M
Byrne, MJ
Vansteenkiste, J
Cosaert, J
LUNG CANCER: CURRENT TOPICS, 2001, : 321 - 324
[22] Weekly docetaxel as second-line chemotherapy in advanced non-small cell lung cancer: Phase II trial
Serke, M
Schoenfeld, N
Loddenkemper, R
ANTICANCER RESEARCH, 2004, 24 (2C) : 1211 - 1216
[23] Which chemotherapy regimen might be the best for the second-line treatment of patients with small-cell lung cancer?
Yildiz, Oguzhan
Karaagac, Mustafa
Eryilmaz, Melek Karakurt
Artac, Mehmet
ONCOLOGY IN CLINICAL PRACTICE, 2021, 17 (06): : 244 - 252
[24] Randomized Phase III Trial of Amrubicin Versus Topotecan As Second-Line Treatment for Patients With Small-Cell Lung Cancer
von Pawel, Joachim
Jotte, Robert
Spigel, David R.
O'Brien, Mary E. R.
Socinski, Mark A.
Mezger, Joerg
Steins, Martin
Bosquee, Leon
Bubis, Jeffrey
Nackaerts, Kristiaan
Trigo, Jose M.
Clingan, Philip
Schuette, Wolfgang
Lorigan, Paul
Reck, Martin
Domine, Manuel
Shepherd, Frances A.
Li, Shaoyi
Renschler, Markus F.
JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (35) : 4012 - U160
[25] A phase II randomised trial comparing the cisplatin-etoposide combination chemotherapy with or without carboplatin as second-line therapy for small-cell lung cancer
Sculier, JP
Lafitte, JJ
Lecomte, J
Berghmans, T
Thiriaux, J
Van Cutsem, O
Efremidis, A
Ninane, V
Paesmans, M
Mommen, P
Klastersky, J
ANNALS OF ONCOLOGY, 2002, 13 (09) : 1454 - 1459
[26] Phase II Study of Amrubicin As Second-Line Therapy in Patients With Platinum-Refractory Small-Cell Lung Cancer
Ettinger, David S.
Jotte, Robert
Lorigan, Paul
Gupta, Vicram
Garbo, Lawrence
Alemany, Carlos
Conkling, Paul
Spigel, David R.
Dudek, Arkadiusz Z.
Shah, Chirag
Salgia, Ravi
McNally, Richard
Renschler, Markus F.
Oliver, Jennifer W.
JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15) : 2598 - 2603
[27] Optimal drugs for second-line treatment of patients with small-cell lung cancer
Rossi, Antonio
Sacco, Paola Claudia
Sgambato, Assunta
Casaluce, Francesca
Santabarbara, Giuseppe
Palazzolo, Giovanni
Maione, Paolo
Gridelli, Cesare
EXPERT OPINION ON PHARMACOTHERAPY, 2016, 17 (07) : 969 - 976
[28] Safety profile of ZD0473 in Phase II trials of patients with advanced cancers
Hoctin-Boes, G
Cosaert, J
Koehler, M
Smith, M
BRITISH JOURNAL OF CANCER, 2001, 85 : 95 - 95
[29] Second-line Chemotherapy for Patients with Small Cell Lung Cancer and Interstitial Lung Disease
Fujimoto, Daichi
Shimizu, Ryoko
Kato, Ryoji
Sato, Yuki
Kogo, Mariko
Ito, Jiro
Teraoka, Shunsuke
Otoshi, Takehiro
Nagata, Kazuma
Nakagawa, Atsushi
Otsuka, Kojiro
Katakami, Nobuyuki
Tomii, Keisuke
ANTICANCER RESEARCH, 2015, 35 (11) : 6261 - 6266
[30] Second-line chemotherapy for non-small-cell lung cancer with monthly docetaxel and weekly gemcitabine: A phase II trial
Spiridonidis, CH
Laufman, LR
Carman, L
Moore, T
Blair, S
Jones, J
George, C
Patel, T
Roach, R
Rupert, R
Zangmeister, J
Colborn, D
Kuebler, JP
ANNALS OF ONCOLOGY, 2001, 12 (01) : 89 - 94

← 1 2 3 4 5 →